Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Cisplatin resistance is complex and involves several different mechanisms. Employing cDNA microarray analysis, we have found that cisplatin resistant cells share the common characteristic of increase in ribosomal proteins and elongation factors. We hypothesize that in order to survive cisplatin treatment, cells have to synthesize DNA repair proteins, antiapoptotic proteins and growth-stimulating proteins. Thus, by blocking the translation of these proteins, one should be able to restore cisplatin sensitivity. We have studied the role of CCI-779, an ester analog of rapamycin which is known to inhibit translation by disabling mTOR, in restoring cisplatin sensitivity in a panel of cisplatin resistant cell lines. We have also determined the role of CCI-779 in P-gp1 and MRP1 mediated resistance. Results: Our data show that CCI-779 possess antiproliferative effects in both cisplatin sensitive and resistant cell lines, but shows no effect in P-gp1 and MRP1 overexpressing cell lines. Importantly, CCI-779 at 10 ng/ml (less that 10% of the growth inhibitory effect) can increase the growth inhibition of cisplatin by 2.5–6 fold. Moreover, CCI-779 also enhances the apoptotic effect of cisplatin in cisplatin resistant cell lines. In these resistant cells, adding CCI-779 decreases the amount of 4E-BP phosphorylation and p-70S6 kinase phosphorylation as well as lower the amount of elongation factor while cisplatin alone has no effect. However, CCI-779 can only reverse P-gp mediated drug resistance at a higher dose(1 ug/ml). Conclusion: We conclude that CCI-779 is able to restore cisplatin sensitivity in small cell lung cancer cell lines selected for cisplatin resistance as well as cell lines derived from patients who failed cisplatin. These findings can be further explored for future clinical use. On the other hand, CCI-779 at achievable clinical concentration, has no growth inhibitory effect in P-gp1 or MRP1 overexpressing cells. Furthermore, CCI-779 also appears to be a weak MDR1 reversal agent. Thus, it is not a candidate to use in MDR1 or MRP1 overexpressing cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“MRP1 also belongs to the ABC transporter superfamily [19-21], however, this efflux pump most likely transports the glutathione conjugated drug.”
BackgroundRegulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545 · cited 1×
“The two best characterized downstream targets of mTOR are two families of proteins that control translation, the ribosomal protein S6 kinase (S6K) and the eukaryotic initiation factor eIF4E binding protein (4E-BP)[12,33-35].”
BackgroundRapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934 · cited 1×
“The two best characterized downstream targets of mTOR are two families of proteins that control translation, the ribosomal protein S6 kinase (S6K) and the eukaryotic initiation factor eIF4E binding protein (4E-BP)[12,33-35].”
Background
Cited by
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Kim, H. K., Choi, I. J., Kim, C. G., Kim, H. S., Oshima, A., Michalowski, A., & Green, J. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016694 · Cited by 135
Metadata
- Authors
- Wu, C., Wangpaichitr, M., Feun, L., Kuo, M. T., Robles, C., Lampidis, T., & Savaraj, N.
- Venue
- Molecular Cancer
- Published
- 2005-07-20
- Volume
- 4
- Issue
- 1
- Pages
- 25-25
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2109566248
- Cited by
- 125
- References
- 4
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. https://app.cochat.ai/papers/10.1186/1476-4598-4-25
- The paper
- Wu, C., Wangpaichitr, M., Feun, L., Kuo, M. T., Robles, C., Lampidis, T., & Savaraj, N. (2005). Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Molecular Cancer. https://doi.org/10.1186/1476-4598-4-25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.